Although, the initial description of irisin was focused on mice, Boström et al. raised the hope that exogenously administered irisin might have a therapeutic potential in the treatment of obesity and diabetes in humans. The gene discussed is FNDC5; the disease is obesity due to melanocortin 4 receptor deficiency.